In terms of leptomeningeal metastases, the BLOOM study showed that a high dose (160 mg once daily) of osimertinib achieved an ORR of 62%, median PFS of 8.6 months and median OS of 11 months in EGFR-mutated NSCLC patients with leptomeningeal metastases [231]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.